Antibiotic regimens often include the sequential changing of drugs to limit development 17 and evolution of resistance of bacterial pathogens. It remains unclear how history of adaptation 18 to one antibiotic can influence the resistance profiles when bacteria subsequently adapt to a 19 different antibiotic. Here, we experimentally evolved Pseudomonas aeruginosa to six two-drug 20 sequences. We observed drug order-specific effects whereby: adaptation to the first drug can 21 limit subsequent adaptation to the second drug, adaptation to the second drug can restore 22 susceptibility to the first drug, or final resistance levels depend on the order of the two-drug 23 sequence. These findings demonstrate how resistance not only depends on the current drug 24 regimen but also history of past regimens. These order-specific effects have profound clinical 25 implications and provide support for the need to consider history of past drug exposure when 26 designing strategies to mitigate resistance and combat bacterial infections. 27 28
Introduction
Antibiotic resistance is a growing healthcare concern whereby bacterial infections are 30 increasingly difficult to eradicate due to their ability to survive antibiotic treatments [1] . There 31 have been reported cases of resistance for nearly every antibiotic we have available [2] . Coupled 32 with the fact that the antibiotic discovery pipeline has slowed over the past few decades [3], there 33 is a dire need to find better treatment strategies using existing antibiotics that can slow or even 34 reverse the development of resistance. 35 Recent studies have explored how adaptation to an antibiotic can cause bacteria to 36 concurrently become more susceptible or more resistant to other drugs, an effect termed 37 collateral sensitivity or collateral resistance [4] [5] [6] . Collateral sensitivities between drugs have 38 3 been used to design drug cycling strategies and to explain the decreased rate of adaptation to 39 certain antibiotics [5, [7] [8] [9] [10] [11] [12] [13] . However, it remains unexplored how prior adaptation to one drug 40 environment affects the evolutionary dynamics of a bacterial population during subsequent 41 adaptation to a second drug in terms of the amount of resistance it can potentially develop and 42 the resistance profile of the first drug. 43 We aim to ask and explore the question of: how does history of adaptation to one drug 44 influence the subsequent adaptation to a second drug? If there are such historical dependencies, 45 can we use this knowledge to design sequential therapies that slow down the evolution of 46 resistance to the drugs used? Additionally, elucidation of any historical dependencies of 47 antibiotic resistance evolution would allow for rational forecasting of future resistance 48 development and would inform clinicians of potential strategies for mitigating antibiotic 49 resistance. To test how different antibiotic resistance backgrounds affect the subsequent adaptation 54 dynamics when evolved to a new antibiotic, we used a laboratory evolution approach to evolve 55 P. aeruginosa to all two-drug sequences of the three clinically relevant drugs piperacillin, 56 tobramycin, and ciprofloxacin. In each of the experimental sequences, P. aeruginosa was 57 subjected to 20 days of adaptation to each drug by serially passaging parallel replicate cultures to 58 increasing concentrations of the drugs followed subsequently by 20 more days of adaptation to 59 each of the three drugs or to LB media without drug ( Fig 1A) . Additional parallel replicates were 60 adapted to LB media without drug for 40 days as a control. For each drug treatment, changes in 61 4 the resistance to the other two drugs were concurrently measured ( Fig 1B) . We observed 62 differences in final resistance levels to the different drugs depending on the history of past 63 treatments (or lack of treatments), an effect we call drug order-specific effects of adaptation (Fig   64   2 ; Fig S1 in S1 Text). Our results show that history of past drug adaptation affects how much 65 resistance can potentially arise when subsequently adapted to a new antibiotic. Furthermore, in 66 some cases, adaptation to a second drug can partially or fully restore sensitivity to the first drug. 67 These observations suggest that in order to limit the development of antibiotic resistance in the 68 clinical setting, it is important to consider which drugs a bacterial pathogen may have been 69 exposed to in the past when choosing which drugs to subsequently deploy. aeruginosa PA14 was evolved daily for twenty days to piperacillin, tobramycin, and 73 ciprofloxacin. In the following twenty days, the single drug-resistant lineages were 74 passaged further to the first drug, as well as sub-passaged to the other two drugs, as well 75 as to LB media. (B) Bacteria were taken from the highest concentration that allowed 76 growth (defined as OD 600 >0.1), diluted in fresh LB by a factor of 1/500, and inoculated 77 into fresh MIC gradients. After overnight incubation, the process is then repeated. The three drugs tested have different mechanisms of action and are clinically used to treat 94 P. aeruginosa infections. Piperacillin (PIP) is a beta-lactam that inhibits cell wall synthesis; 95 tobramycin (TOB) is an aminoglycoside that binds to the prokaryote ribosome and inhibits 96 protein synthesis; and ciprofloxacin (CIP) is a fluoroquinolone that binds DNA gyrase and 97 inhibits DNA synthesis. Adaptive evolution for 20 days to these drugs individually resulted in 98 single drug-resistant mutants denoted PIP R , TOB R , and CIP R . Day 20 PIP R , TOB R and CIP R had 99 averages of 32-, 64-, and 64-times higher minimum inhibitory concentrations (MICs) to 100 piperacillin, tobramycin, and ciprofloxacin, respectively, compared to their initial levels. 101 By following how the resistance to each of the three drugs changes for each of the drug 102 sequences (Fig S1 and S2 in S1 Text and S1 Data), we observed three types of drug order-103 specific effects in the MIC profiles. In the first type, prior adaptation to a first drug prevents the 104 subsequent adaptation to a second drug (compared to the amount of resistance developed when 105 the Day 0 Ancestor is evolved to the second drug). Evolution first to piperacillin limits the 106 subsequent evolution to tobramycin (MIC TOB ) ( Fig 2D and 2K ), compared to evolving the 107 6 ancestor to tobramycin (Day 40 PIP R TOB R vs. Day 20 TOB R ) ( Fig 2E) . Also, evolution to 108 tobramycin first limits the subsequent evolution to ciprofloxacin (MIC CIP ) ( Fig 2H and 2L) , 109 compared to evolving the ancestor to ciprofloxacin (Day 40 TOB R CIP R vs Day 20 CIP R ) ( Fig   110   2I ). This observation suggests that in some cases, if one is presented with an infection that is 111 resistant to one drug, the potential for developing high resistance to a second drug can be limited 112 if the second drug is rationally selected. Interestingly, we observed no cases where prior 113 adaptation to one drug led to enhancement in the adaptation to a second drug. 114 In the second type of order-specific effects, adaptation to a second drug restores the 115 susceptibility to the first drug. This partial or full restoration of sensitivity to the first drug can be 116 explained by two scenarios: as a direct consequence of adaptation to the second drug, or as a 117 consequence of simply not being exposed anymore to the first drug. We observed that to when it was evolved to tobramycin or LB. In additional cases, we saw that subsequent 126 evolution to ciprofloxacin after piperacillin (Day 40 PIP R CIP R ) ( Fig 2A) and tobramycin (Day 40 127 TOB R CIP R ) ( Fig 2E) restores the susceptibility to piperacillin (MIC PIP ) and tobramycin 128 (MIC TOB ), respectively. In the former case, the results suggest that the subsequent ciprofloxacin 129 adaptation was directly involved in the piperacillin resensitization since evolution of Day 20 130 7 PIP R to LB did not cause the MIC PIP to decrease significantly (Fig 2A and 2J ). In the latter case, 131 evolution to Day 20 TOB R to ciprofloxacin and LB led to comparable levels of tobramycin 132 resensitization ( Fig 2E and 2K) , which indicates that the decrease in MIC TOB may be attributed to 133 the removal of the tobramycin pressure. Of note, Day 40 TOB R PIP R had a comparable MIC TOB 134 to Day 20 TOB R , suggesting that the subsequent piperacillin adaptation actively contributed to 135 the maintenance of the high tobramycin resistance ( Fig 2E) . These cases where partial or full 136 resensitization to the first drug occurs after adaptation to a second drug or LB highlight 137 opportunities where resistance to one drug can potentially be reversed by treating with a second 138 drug or by removing the drug pressure completely. 139 The last type of order-specific effects exists as a consequence of the first two types 140 whereby the MIC of a drug used in a two-drug sequence is higher in one sequence than the than the reverse (TOB R CIP R ) ( Fig 2B) . These cases highlight how treating an infection with a 150 sequence of two drugs can result in different resistance profiles depending on the order used. 151 Hence, of all the two-drug sequences tested, TOB-CIP is potentially a good sequential 152 therapy because prior tobramycin evolution limits subsequent ciprofloxacin evolution ( Fig 2H) , 153 8 which in turn partially restores sensitivity to tobramycin ( Fig 2E) due to removal of the 154 tobramycin pressure. Other interesting outcomes include the following: adaptation to tobramycin 155 followed by subsequent adaptation to ciprofloxacin (Day 40 TOB R CIP R ) resulted in a decreased 156 MIC PIP compared to single-drug adaptation to tobramycin (Day 20 TOB R ) ( Fig 2B) . Similarly, 157 adaptation to piperacillin followed by subsequent adaptation to ciprofloxacin (Day 40 PIP R CIP R ) 158 resulted in a decreased MIC TOB compared to single-drug adaptation to piperacillin (Day 20 PIP R ) 159 ( Fig 2D) . In these two cases, ciprofloxacin evolution after prior piperacillin or tobramycin 160 evolution results in sensitization to the third (unexposed) drug. Lastly, while ciprofloxacin 161 evolution (Day 20 CIP R ) leads to collateral sensitivity to piperacillin (MIC PIP ), subsequent 162 tobramycin evolution (Day 40 CIP R TOB R ) restores MIC PIP to initial levels ( Fig 2C) . In contrast, 163 while ciprofloxacin evolution also leads to collateral sensitivity to tobramycin (MIC TOB ), 164 subsequent piperacillin evolution (Day 40 CIP R PIP R ) does not restore MIC TOB to initial levels 165 ( Fig 2F) . Interestingly, a recent study where P. aeruginosa ATCC 27853 was evolved to 166 different antibiotics reported that evolution to tobramycin resulted in collateral sensitivity to 167 piperacillin-tazobactam and ciprofloxacin, whereas we did not observe this effect ( Figure 2B and 168 2H) [14] . Also, this study did not observe adaptation to ciprofloxacin to result in collateral 169 sensitivity to piperacillin and tobramycin, as we reported here. We suspect that these 170 inconsistences may be due to strain-specific differences in the different P. aeruginosa strains 171 used (strain PA14 was used in this study). 172 Genomic mutations of adapted lineages 173 We hypothesized that genomic mutations acquired during the adaptive evolution Table S1 , and Table S2 in S1 Text). 179 The 77 SNPs were found within 49 genes. Two SNPs were synonymous and six were intergenic. While some genes were mutated during evolution to all drugs, other mutations were drug-196 specific and were related to their primary mechanisms of action as would be expected (Table S4   197 in S1 Text). Genes encoding transcriptional regulators for multidrug efflux pumps were 198 commonly mutated during evolution to all three drugs (mexC, mexR, mexS, nalC, nalD, nfxB, 199 10 parS) [15] . Ribosomal proteins (rplJ, rplL, rpsL, rplF) [16] and NADH dehydrogenase subunits 200 (nuoB, nuoG, nuoL, and nuoM) [17, 18] were frequently mutated during tobramycin evolution. 201 The most commonly mutated gene was fusA1, which encodes elongation factor G, and was 202 mutated in 11 different lineages adapted to tobramycin. fusA1 has been observed to be mutated in 203 clinical isolates of P. aeruginosa [19] [20] [21] as well as in adaptive evolution studies to 204 aminoglycosides in P. aeruginosa [14] and E. coli [7, 8] . Mutations in fusA1 may also contribute 205 to altered intracellular (p)ppGpp levels, which may modulate virulence in P. aeruginosa [21] . 206 Mutations in gyrA and gyrB were observed during ciprofloxacin evolution, but none were 207 observed in parC and parE (the other genes of the quinolone resistance determining region [22]). 208 Lastly, genes encoding peptidoglycan synthesis enzymes (dacC, mpl) and beta-lactamase 209 regulators (ampR) were mutated during piperacillin treatment. Many of these genes have also 210 been observed to be mutated during human host adaptation of P. aeruginosa [23], further 211 highlighting the need to study these history-dependent evolutionary dynamics (also, see 212 Supplementary text in S1 Text). Overall, we did not see a clear pattern of mutated genes that 213 explain the differences in the drug order-specific effects. This idea that genomic mutations are 214 not the only determinants of the differences in resistance profiles is consistent with other 215 experimental evolution studies in E. coli [24] and P. aeruginosa [14] . 216 Hysteresis of pyomelanin hyperproduction 217 One striking mutation we observed was that three of the four replicates of Day 20 PIP R 218 had large, ~400 kbp deletions in a conserved region of the chromosome (Fig 3; S2 Data) , 219 suggestive of selective genome reduction (18-21) and have been associated with directed repeats (Fig 4B) or Day 20 CIP R (Fig 4C) . Still, certain lineages starting 248 from Day 20 TOB R and Day 20 CIP R did also produce pyomelanin, albeit with less propensity 249 than starting from Day 0 Ancestor (Fig 4D; Fig S4 in S1 Text) . Drug order-specific effects in clinical isolates 269 To explore the relevance of our laboratory evolution results clinically, we tested for the 270 drug order-specific MIC evolutionary dynamics in clinical isolates. We evolved three 271 piperacillin-resistant clinical isolates of P. aeruginosa to piperacillin, tobramycin and 272 ciprofloxacin for ten days and tracked how the piperacillin resistance changed in these lineages. 273 If the results from the adaptive evolution experiment applied to these piperacillin-resistant 274 clinical isolates, then we would expect that evolving to tobramycin would not affect the 275 piperacillin resistance, but evolving to ciprofloxacin would restore susceptibility to piperacillin. 276 As mentioned previously, evolving Day 20 PIP R to LB did not result in a reduction of MIC PIP , 277 which suggests that the resensitization to piperacillin when Day 20 PIP R was evolved to 278 ciprofloxacin is a consequence of the switch to a ciprofloxacin drug pressure. Of the three 279 isolates we tested, isolates #2 and #3 matched these expectations (Fig 5B and 5C ). This 280 observation suggests that the MIC evolutionary dynamics we observed is not limited to 281 laboratory strains of P. aeruginosa and is clinically relevant. In the isolate #1, MIC PIP of the 282 ciprofloxacin-evolved lineages was not significantly less than that of the tobramycin-evolved 283 lineages ( Fig 5A) . Interestingly, this isolate evolved to higher levels of piperacillin and 284 ciprofloxacin resistance than the other two isolates (S1 Data and Fig S5 in S1 Text) which 285 suggests the possibility that adaptation to ciprofloxacin in these higher piperacillin-resistant 286 cultures could still result in a restoration of piperacillin susceptibility. isolate (denoted A WT , B WT , C WT , and D WT ) is the presence of large chromosomal deletions that 308 overlap with parts of the deletions seen in Day 20 PIP R -1, -2, and -3 ( Fig 6E; S2 Data) . Indeed, 309 all of the large deletions encompass hmgA, whose loss accounts for the pyomelanin phenotype. 310 We used these four pairs of clinical isolates to test the hypothesis that the large deletions play a 311 role limiting the amount of tobramycin resistance that can be developed. We evolved the four 312 pairs of isolates to tobramycin using the same daily serial passaging technique used throughout 313 this study and tracked the MICs of tobramycin, piperacillin, and ciprofloxacin over the course of 314 15 15 days. At the end of the 15 days, we saw that A PM , B PM , and C PM had lower relative increases 315 in MIC TOB , compared to A WT , B WT , and C WT , respectively (Fig 6A-C ; S1 Data). This data then 316 provides support for the idea that the large chromosomal deletions indeed do play a role in 317 limiting the maximum level of tobramycin resistance that can be developed. In the case of the 318 fourth pair, we saw that D WT and D PM had comparable increases in MIC TOB over the course of 319 the tobramycin adaptation ( Fig 6D) . It can be speculated that some combination of the presence 320 or loss of specific genes in D PM led to this evolutionary trajectory that is different from the other 321 three pyomelanogenic isolates. We would also like to point out that within each pair, the "WT" Interestingly, a recent study also observed large genomic deletions spanning hmgA when 339 P. aeruginosa PAO1 was evolved to meropenem, which is another beta-lactam antibiotic [26] . 340 These mutants were also pyomelanogenic. The large deletions in both our study as well as this 341 recent study also span mexX and mexY, which encode portions of the efflux pump that is a 342 significant determinant of aminoglycoside resistance [29]. The loss of these genes in the three 343 PIP R replicates may partially explain why subsequent tobramycin adaptation is limited compared 344 to the replicate that did not sustain the large deletion. . 360 There are several factors involved in the emergence of antibiotic resistance that are 361 clinically important that are not considered in this study. We have not taken into account any of 362 the pathogen/host interactions such as the role of the immune system. We neglect to consider the 363 role of horizontal gene transfer, which is a common mechanism of antibiotic resistance transfer, 364 and focus rather on the role of de novo mutations acquired during adaptation. Because of the 365 nature of the serial passaging method, we may be selecting for fast growers that may not 366 necessarily have mutations that confer the most amount of resistance in terms of the MIC. We 367 used a strong selection pressure in this study by propagating from the highest concentration of 368 drug that showed growth, but it has been shown that weak antibiotic selection pressure can 369 greatly affect the adaptive landscape [37, 38] . Lastly, these bacteria were evolved to one 370 18 antibiotic at a time and we do not know how different mutant lineages would adapt if competed 371 against each other. It would be interesting in the future to conduct competition experiments to 372 measure the fitness of the different lineages with respect to each other. 373 While adaptive evolution of clinical isolates suggests that the drug order-specific effects 374 are clinically relevant, actual clinical studies must be performed to test the true clinical 375 applicability of these effects. A major challenge that still needs to be addressed is how to 376 translate the results of in vitro adaptive evolution experiments to effective therapies that can be 377 used in an actual clinical setting [39] . For example, in this study, we saw that in vitro adaptation 378 to piperacillin starting from wild-type P. aeruginosa often led to large chromosomal deletions 379 and concomitant pyomelanin hyperproduction. However, the clinical isolates we analyzed (with 380 data in Fig 5) were used to test the hypothesis that P. aeruginosa with high piperacillin resistance 381 would become resensitized to piperacillin if adapted to ciprofloxacin. Yet, none of these isolates 382 were pyomelanogenic. On the other hand, the pyomelanogenic clinical isolates from Fig 6 were   383 used to test the hypothesis that P. aeruginosa with large chromosomal deletions would evolve 384 less tobramycin resistance than their parental counterparts, yet these pyomelanin producing 385 isolates were not more resistant to piperacillin. The evolution of these different sets of clinical 386 isolates helped to support the concept of the drug order-specific effects that were uncovered in 387 the main adaptive evolution experiment. However, it would seem that the former set of isolates 388 were phenotypically representative of Day 20 PIP R in terms of high MIC PIP , while the latter set 389 of isolates were genetically representative of Day 20 PIP R in terms of having the large 390 chromosomal deletions. Disparities between the phenotypic and genetic adaptations such as this 391 will need to be studied further in terms of strain-specific differences, actual history of antibiotic 392 exposure, and other factors that are beyond the scope of this study. 393 19 Despite these caveats, there are several key factors of this study that provide confidence 394 in the claims made. We saw consistency in the parallel replicates for the treatment lineages. An 395 interesting exception is Day 40 PIP R TOB R -4, which had a higher final tobramycin resistance 396 compared to Day 40 PIP R TOB R -1,-2 and -3, which we believe is attributed to the large genomic 397 deletions seen in the first three replicates, but not in the fourth replicate. We observed parallel 398 evolution where several genes were mutated independently across multiple lineages, and overall 399 there were less than 15 mutations per 20 days of evolution, and these two observations suggest 400 positive selection. Furthermore, many of the mutated genes are observed in clinical isolates of P. These history-specific effects have direct clinical implications on optimizing antibiotic treatment 408 strategies to slow and prevent the emergence of dangerous multidrug resistant bacterial 409 pathogens. We believe that these effects must be taken into account for an antibiotic stewardship 410 program to have success in promoting the appropriate use of antibiotics.
412

Materials and Methods
413
Experimental study design 414 We evolved in parallel four independent replicates for each evolution lineage in the 415 primary adaptive evolution experiment, and three independent replicates for each of the clinical 416 20 isolates to balance the statistical power of the conclusions with the technical feasibilities of the 417 daily serial propagations. In the primary adaptive evolution experiment, we concluded the single-418 drug evolution at the end of 20 days because the resistance levels of the evolved lineages to their 419 respective drugs were saturated or close to saturated at that point. The clinical isolates from Fig 5   420 and from Fig 6 were evolved for ten and fifteen days, respectively because the similarities and 421 differences of the drug-specific effects to those of the primary adaptive evolution experiment 422 were readily apparent at that point. 423 Media, growth conditions, and antibiotics 424 MIC plates were made daily using the broth microdilution method with the standard two-425 fold dilution series (34). Lysogeny broth was used as the growth medium for all experiments (1% 426 tryptone, 0.5% yeast extract, 1% NaCl). Antibiotics tested include piperacillin sodium, 427 tobramycin, and ciprofloxacin HCl (Sigma). Aliquots of 1 mg/ml and 10 mg/ml antibiotic stocks 428 were made by diluting the antibiotic powders in LB and were stored at -20°C. New frozen drug 429 aliquots were used on a daily basis. 430 Adaptive laboratory evolution 431 A frozen stock of P. aeruginosa PA14 was streaked on an LB agar plate and a single 432 colony was inoculated into 4 ml of LB, which was then grown overnight at 37°C, shaking at 125 433 RPM. This antibiotic-susceptible culture, denoted as the Day 0 Ancestor, was diluted to an OD 600 434 of 0.001 (approximately 10 6 CFU/ml), and then inoculated into three identical MIC plates. A 435 sample of the ancestor was saved in 25% glycerol and stored at -80°C. The three MIC plates 436 were used to serially propagate cultures evolved to LB media, piperacillin, and tobramycin, with 437 four biological replicates per condition. Wells for growth control (media+culture) and sterility 438 control (media) were included in each MIC plate. MIC plates were placed in a plastic container 439 21 (to prevent evaporation) and incubated at 37°C with shaking at 125 RPM (Thermo Scientific 440 MaxQ 4000). MIC plates were incubated daily for ~23 hours. 441 At the end of incubation, growth in the MIC plates was determined using a plate reader 442 (Tecan Infinite M200 Pro). Growth was defined as OD 600 > 0.1 after background subtraction. We 443 recorded the MIC of each lineage for each drug, which was defined as the lowest antibiotic 444 concentration tested that did not show growth. To propagate, cultures were passaged from the 445 highest concentration that showed growth (i.e. MIC/2) from the corresponding MIC drug 446 gradient. For adaptation to LB, cultures were passaged from the growth control well that 447 contained only LB without drug. For each culture to be passaged, the culture was first diluted by 448 a factor of 1/250 in fresh LB (e.g. 20 μ l of the culture was diluted in 5 ml of LB), which was then 
